Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This study found that tumor immunotherapy, while effective against solid tumors, can disrupt the immune balance in hair follicles, causing follicular toxicity and alopecia, highlighting the need for targeted interventions to manage these adverse effects.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.